[Current status and future perspective of sorafenib for advanced hepatocellular carcinoma]

Nihon Shokakibyo Gakkai Zasshi. 2012 Aug;109(8):1346-54.

[Article in Japanese]

Authors

Masafumi Ikeda¹, Shuichi Mitsunaga, Satoshi Shimizu, Izumi Ohno, Hideaki Takahashi, Hiroyuki Okuyama, Akiko Kuwahara, Takuji Okusaka

Affiliation

¹ Division of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, Japan. masikeda@east.ncc.go.jp

PMID: 22863957

No abstract available

Publication types

Review

MeSH terms

Antineoplastic Agents / administration & dosage
Antineoplastic Agents / adverse effects
Antineoplastic Agents / therapeutic use*
Carcinoma, Hepatocellular / drug therapy*
Humans
Liver Neoplasms / drug therapy*
Niacinamide / administration & dosage
Niacinamide / adverse effects
Niacinamide / analogs & derivatives*
Niacinamide / therapeutic use
Phenylurea Compounds / administration & dosage
Phenylurea Compounds / adverse effects
Phenylurea Compounds / therapeutic use*
Sorafenib

Substances

Antineoplastic Agents
Phenylurea Compounds
Niacinamide
Sorafenib